ribosomal protein SA pseudogene 9Genealiases: LAMR1P9 · RPSA_20_986
Q-omics provides the consensus-scored RPSAP9 profile across patient tissues and cancer cell-line models. RPSAP9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPSAP9 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPSAP9 RNA expression shows 16,936 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RPSAP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP9 survival associations across molecular data types. RPSAP9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP9 RNA expression–survival associations across cancer types. High RPSAP9 expression shows unfavorable associations in ACC, KIRC, LUAD, LGG, LIHC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPSAP9 RNA expression.
This table summarizes RPSAP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP9 shows lower tumor expression in COAD, LUSC and KICH and higher tumor expression in LIHC, THCA and STAD. The COAD box plot shows higher RPSAP9 RNA expression in normal versus tumor tissue (log2 FC = −0.808, t-test p < 0.001).
This table shows molecular features associated with RPSAP9 in patient tissues and cancer cell lines. In patient samples, RPSAP9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPSAP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
